Sionna Therapeutics (NASDAQ:SION) Upgraded at Wall Street Zen

by · The Markets Daily

Wall Street Zen upgraded shares of Sionna Therapeutics (NASDAQ:SION – Free Report) from a sell rating to a hold rating in a research report report published on Saturday.

A number of other equities research analysts have also recently commented on the stock. Raymond James Financial restated a “strong-buy” rating on shares of Sionna Therapeutics in a research note on Wednesday, November 5th. Weiss Ratings restated a “sell (e+)” rating on shares of Sionna Therapeutics in a research note on Monday, December 8th. Jones Trading started coverage on shares of Sionna Therapeutics in a report on Monday, September 8th. They issued a “buy” rating and a $46.00 target price for the company. BTIG Research started coverage on Sionna Therapeutics in a research note on Wednesday, November 19th. They issued a “buy” rating and a $50.00 price target for the company. Finally, Royal Bank Of Canada restated an “underperform” rating and issued a $24.00 price objective on shares of Sionna Therapeutics in a research report on Monday, December 1st. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $40.33.

Check Out Our Latest Research Report on Sionna Therapeutics

Sionna Therapeutics Stock Performance

NASDAQ:SION opened at $42.76 on Friday. The stock has a 50-day simple moving average of $37.64 and a two-hundred day simple moving average of $26.62. Sionna Therapeutics has a 52-week low of $7.26 and a 52-week high of $45.00. The firm has a market capitalization of $1.91 billion and a PE ratio of -8.78.

Sionna Therapeutics (NASDAQ:SION – Get Free Report) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.06.

Insiders Place Their Bets

In related news, Director Orbimed Advisors Llc sold 1,600 shares of the business’s stock in a transaction on Wednesday, November 26th. The shares were sold at an average price of $44.49, for a total value of $71,184.00. Following the sale, the director owned 3,596,886 shares in the company, valued at approximately $160,025,458.14. The trade was a 0.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Peter A. Thompson sold 1,600 shares of the company’s stock in a transaction on Wednesday, November 26th. The shares were sold at an average price of $44.49, for a total transaction of $71,184.00. Following the sale, the director directly owned 3,596,886 shares in the company, valued at approximately $160,025,458.14. The trade was a 0.04% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 1,604,841 shares of company stock valued at $58,312,100 in the last quarter. 3.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Sionna Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. RA Capital Management L.P. purchased a new stake in shares of Sionna Therapeutics during the 1st quarter valued at about $109,258,000. TPG GP A LLC bought a new stake in Sionna Therapeutics during the first quarter worth approximately $69,925,000. Atlas Venture Life Science Advisors LLC purchased a new stake in Sionna Therapeutics during the first quarter valued at approximately $38,639,000. Viking Global Investors LP lifted its stake in shares of Sionna Therapeutics by 8.2% in the 2nd quarter. Viking Global Investors LP now owns 3,195,181 shares of the company’s stock valued at $55,436,000 after purchasing an additional 242,427 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in shares of Sionna Therapeutics by 2.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 2,221,188 shares of the company’s stock valued at $38,538,000 after purchasing an additional 51,589 shares during the last quarter.

Sionna Therapeutics Company Profile

(Get Free Report)

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.

Recommended Stories